Caribou Biosciences
CRBU
137 hedge funds and large institutions have $71.3M invested in Caribou Biosciences in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 27 increasing their positions, 39 reducing their positions, and 13 closing their positions.
208% more call options, than puts
Call options by funds: $751K | Put options by funds: $244K
115% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 13
20% more capital invested
Capital invested by funds: $59.6M → $71.3M (+$11.8M)
10% more funds holding
Funds holding: 124 → 137 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.57% less ownership
Funds ownership: 39.73% → 39.16% (-0.57%)
31% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.63M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$1.62M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.49M |
| 4 |
Two Sigma Investments
New York
|
+$1.27M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$557K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$799K |
| 2 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$724K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$650K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$612K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$571K |
CRBU Hedge Fund Activity: Q1 2026 in Review
137 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q1 2026, worth a combined $71.3M — up 20% from $59.6M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CRBU positions and 13 closed out — a net gain of 15 holders — while 27 added to existing stakes and 39 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.63M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $799K.
- 137 institutional investors held Caribou Biosciences (CRBU) as of Q1 2026, up from 124 in Q4 2025.
- Funds reported $71.3M of Caribou Biosciences stock for Q1 2026, up 20% quarter-over-quarter.
- 28 funds opened new Caribou Biosciences positions in Q1 2026 and 13 closed out, a net change of +15 holders.
- The largest Caribou Biosciences buyer in Q1 2026 was Renaissance Technologies, an estimated $1.63M added.
- The largest Caribou Biosciences seller in Q1 2026 was Jacobs Levy Equity Management, an estimated $799K sold.
Based on aggregated 13F filings for Q1 2026.